Drug Profile
SP 20104
Alternative Names: SP20104Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class Urologics
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Focal segmental glomerulosclerosis
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Focal segmental glomerulosclerosis in USA (unspecified route) (Sarfez Pharmaceuticals pipeline, October 2021)
- 23 Jan 2018 SP 20104 is still in phase II trials for Focal segmental glomerulosclerosis in USA (Sarfez Pharmaceuticals, January 2018)
- 24 Nov 2017 Sarfez announces intention to submit NDA to US FDA for Focal segmental glomerulosclerosis in the third quarter of 2019 (Sarfez pipeline, November 2017)